Your browser doesn't support javascript.
loading
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.
Vlaar, Alexander P J; de Bruin, Sanne; Busch, Matthias; Timmermans, Sjoerd A M E G; van Zeggeren, Ingeborg E; Koning, Rutger; Ter Horst, Liora; Bulle, Esther B; van Baarle, Frank E H P; van de Poll, Marcel C G; Kemper, E Marleen; van der Horst, Iwan C C; Schultz, Marcus J; Horn, Janneke; Paulus, Frederique; Bos, Lieuwe D; Wiersinga, W Joost; Witzenrath, Martin; Rueckinger, Simon; Pilz, Korinna; Brouwer, Matthijs C; Guo, Ren-Feng; Heunks, Leo; van Paassen, Pieter; Riedemann, Niels C; van de Beek, Diederik.
Afiliación
  • Vlaar APJ; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • de Bruin S; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • Busch M; Department of Immunology, Maastricht UMC, Maastricht, Netherlands.
  • Timmermans SAMEG; Department of Immunology, Maastricht UMC, Maastricht, Netherlands.
  • van Zeggeren IE; Department of Neurology, Amsterdam Neuroscience, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • Koning R; Department of Neurology, Amsterdam Neuroscience, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • Ter Horst L; Department of Neurology, Amsterdam Neuroscience, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • Bulle EB; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • van Baarle FEHP; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • van de Poll MCG; Department of Intensive Care, Maastricht UMC, Maastricht, Netherlands.
  • Kemper EM; Clinical Pharmacy, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • van der Horst ICC; Department of Intensive Care, Maastricht UMC, Maastricht, Netherlands.
  • Schultz MJ; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • Horn J; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • Paulus F; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • Bos LD; Department of Intensive Care, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • Wiersinga WJ; Department of Infectious Diseases, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • Witzenrath M; Department of Infectious Diseases and Respiratory Medicine, Division of Pulmonary Inflammation, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Rueckinger S; Metronomia Clinical Research, Munich, Germany.
  • Pilz K; InflaRx, Jena, Germany.
  • Brouwer MC; Department of Neurology, Amsterdam Neuroscience, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
  • Guo RF; InflaRx Pharmaceuticals, Ann Arbor, MI, USA.
  • Heunks L; Department of Intensive Care, Free University, Amsterdam UMC, Amsterdam, Netherlands.
  • van Paassen P; Department of Immunology, Maastricht UMC, Maastricht, Netherlands.
  • Riedemann NC; InflaRx, Jena, Germany.
  • van de Beek D; Department of Neurology, Amsterdam Neuroscience, University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Lancet Rheumatol ; 2(12): e764-e773, 2020 Dec.
Article en En | MEDLINE | ID: mdl-33015643

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Lancet Rheumatol Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Lancet Rheumatol Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido